H.C. Wainwright lowered the firm’s price target on Intellia Therapeutics (NTLA) to $25 from $30 and keeps a Buy rating on the shares. The firm updated the company’s model post the earnings report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics Reports Q2 2025 Progress and Financials
- Intellia Therapeutics: Strategic Advancements and Promising Clinical Trials Justify Buy Rating
- Intellia Therapeutics: Strategic Advancements and Promising Clinical Developments Drive Buy Rating
- Intellia Therapeutics price target lowered to $21 from $25 at RBC Capital
- Intellia Therapeutics Announces Executive Retirement